Kensey Nash Reports Results From TriActiv Study

Kensey Nash announced the final results of the FIRST (First European Investigation Regarding the Systematic use of the TriActiv Device) Study which was designed to examine cost-effectiveness of the TriActiv System in saphenous vein graft patients, to support reimbursement for the device in Germany and European countries. The data was presented recently at the German Society of Cardiology Meeting in Mannheim, Germany. The TriActiv System is an embolic protection system used during saphenous vein graft interventions to minimize major complications and is commercialized in both the U.S. and Europe.

Yahoo News (http://biz.yahoo.com/prnews/050418/phm028.html?.v=7)